A long-term extension study for the phase 3 study of nalmefene (339-14-001) in patients with alcohol dependence

Trial Profile

A long-term extension study for the phase 3 study of nalmefene (339-14-001) in patients with alcohol dependence

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Nalmefene (Primary)
  • Indications Alcoholism
  • Focus Adverse reactions
  • Sponsors Lundbeck A/S; Otsuka Pharmaceutical
  • Most Recent Events

    • 22 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 10 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top